Actively Recruiting
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Led by Beijing InnoCare Pharma Tech Co., Ltd. · Updated on 2025-09-11
70
Participants Needed
1
Research Sites
312 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
CONDITIONS
Official Title
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Diagnosis of advanced solid tumors or primary central nervous system tumors harboring NTRK gene fusions confirmed by a central laboratory
- No previous treatment with an NTRK inhibitor
- At least one measurable lesion according to RECIST1.1, RANO, or INRC criteria
- Organ functions meeting clinical criteria
You will not qualify if you...
- Unstable primary central nervous system tumors or CNS metastasis
- Abnormal QTc interval or other significant ECG abnormalities at screening
- Recent anti-tumor or other treatments as specified in the protocol
- Grade 1 or higher toxicities from previous treatments that have not recovered
- Other conditions deemed unsuitable for participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
R
Ruihua Xu
CONTACT
Y
Yuhong Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here